News Release

December 3, 2007

JENEX ANNOUNCES $2 MILLION PRIVATE PLACEMENT

Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN, Frankfurt: JNX) announces a Private Placement for gross proceeds of $2 million with a scheduled closing date to be on or about December 14, 2007.

The Private Placement will consist of 20 million Units at a price of $0.10 per Unit. Each Unit will consist of one common share and one half of one share purchase warrant to purchase one whole share for $0.15 for a period of 24 months.

Use of proceeds will be for marketing, advertising, education and awareness programs for the Company’s two products – interceptCS and Therapik.

The Private Placement will be subject to the customary four month hold period from date of issue and TSX-V approval.

About The Jenex Corporation

Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.

In addition to interceptCS, Jenex markets Therapik® for insect stings & bites. Therapik immediately relieves the pain & itch caused by over 20,000 different insects. Therapik is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.

Jenex's Thermal Therapy technology is patented in the U.S, Canada, Australia, & Europe.

For further information on The Jenex Corporation contact:

Michael A. Jenkins,

Tele:(905) 632-3830

Facsimile: (905) 632-3774  

Email: jenex@jenexcorp.com

www.JenexCorp.com

www.interceptCS.com

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events